DK0646008T3 - Minimering af gennemblødning i forbindelse med progestin - Google Patents

Minimering af gennemblødning i forbindelse med progestin

Info

Publication number
DK0646008T3
DK0646008T3 DK93913781T DK93913781T DK0646008T3 DK 0646008 T3 DK0646008 T3 DK 0646008T3 DK 93913781 T DK93913781 T DK 93913781T DK 93913781 T DK93913781 T DK 93913781T DK 0646008 T3 DK0646008 T3 DK 0646008T3
Authority
DK
Denmark
Prior art keywords
progestin
minimization
soaking
progesting
contraceptives
Prior art date
Application number
DK93913781T
Other languages
English (en)
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Application granted granted Critical
Publication of DK0646008T3 publication Critical patent/DK0646008T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93913781T 1992-05-06 1993-05-03 Minimering af gennemblødning i forbindelse med progestin DK0646008T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1992/003574 WO1993021926A1 (en) 1992-05-06 1992-05-06 Minimizing progestin associated breakthrough bleeding
PCT/US1993/004003 WO1993021927A1 (en) 1992-05-06 1993-05-03 Minimizing progestin associated breakthrough bleeding

Publications (1)

Publication Number Publication Date
DK0646008T3 true DK0646008T3 (da) 2000-05-15

Family

ID=22231028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93913781T DK0646008T3 (da) 1992-05-06 1993-05-03 Minimering af gennemblødning i forbindelse med progestin

Country Status (17)

Country Link
EP (1) EP0646008B1 (da)
JP (1) JP3937240B2 (da)
KR (1) KR950700745A (da)
CN (1) CN1073422C (da)
AT (1) ATE187644T1 (da)
AU (2) AU1918092A (da)
CA (1) CA2131911C (da)
DE (1) DE69327319T2 (da)
DK (1) DK0646008T3 (da)
ES (1) ES2142345T3 (da)
FI (1) FI945207A (da)
GR (1) GR3032797T3 (da)
NO (1) NO308581B1 (da)
NZ (1) NZ253405A (da)
PT (1) PT646008E (da)
WO (2) WO1993021926A1 (da)
ZA (1) ZA933153B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
CA2205897A1 (en) * 1994-11-22 1996-05-30 Malcolm Cecil Pike Compositions and methods for contraception and for treatment of benign gynecological disorders
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
JPH10512889A (ja) * 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
WO1997049407A1 (en) * 1996-06-25 1997-12-31 Akzo Nobel N.V. Progestogen-anti-progestogen regimens
KR20010032056A (ko) * 1997-11-14 2001-04-16 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 황체 호르몬-항 황체 호르몬 투약법
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
DE60014358D1 (de) * 1999-04-29 2004-11-04 Akzo Nobel Nv Verwendung von org 33245 in der kombinierten intermittierenden hormontherapie und empfängnisverhütung
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935617B (en) * 1992-08-14 1994-03-07 Akzo Nv Antiprogestogen containing contraceptives.

Also Published As

Publication number Publication date
NZ253405A (en) 1997-06-24
GR3032797T3 (en) 2000-06-30
AU4368593A (en) 1993-11-29
NO944210L (no) 1994-11-04
AU667729B2 (en) 1996-04-04
ATE187644T1 (de) 2000-01-15
CA2131911C (en) 2005-12-27
JPH08509456A (ja) 1996-10-08
FI945207A0 (fi) 1994-11-04
DE69327319D1 (de) 2000-01-20
EP0646008B1 (en) 1999-12-15
ES2142345T3 (es) 2000-04-16
WO1993021927A1 (en) 1993-11-11
AU1918092A (en) 1993-11-29
NO308581B1 (no) 2000-10-02
FI945207A (fi) 1994-11-04
NO944210D0 (no) 1994-11-04
ZA933153B (en) 1993-12-06
KR950700745A (ko) 1995-02-20
PT646008E (pt) 2000-04-28
CN1079651A (zh) 1993-12-22
EP0646008A4 (en) 1995-10-11
CA2131911A1 (en) 1993-11-11
CN1073422C (zh) 2001-10-24
EP0646008A1 (en) 1995-04-05
WO1993021926A1 (en) 1993-11-11
JP3937240B2 (ja) 2007-06-27
DE69327319T2 (de) 2000-07-13

Similar Documents

Publication Publication Date Title
DK0646008T3 (da) Minimering af gennemblødning i forbindelse med progestin
FI963424A0 (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
GB8821049D0 (en) Method & composition for treatment & prevention of viral infections
HK1001717A1 (en) Combinations of viscoelastics for use during surgery
ATE138918T1 (de) Neue chroman- und thiochromanderivate
GR900100326A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
DZ1910A1 (fr) Nouvelles streptogramines et procédé de préparation de streptogramines par mutasynthèse.
FI945000A0 (fi) Menetelmä (S)-amino-1-substituoitujen pyrrolidiinien valmistamiseksi
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
KR870700362A (ko) 항녹내장 조성물 및 이의 제조방법
DE69119900D1 (de) Verwendung von Prostaglandin F3alpha als okulares Hypotensivum
SE8900685D0 (sv) New compounds
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.